Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Weller

Showing results (711-720 of 831) with videos related to

Pageof 84
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2013
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapyMarkus Weiler, Jonas Blaes, Stefan Pusch, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 4, 2025
Availability and use of PET in patients with brain tumours - a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) surveyMaximilian J Mair, Philipp Lohmann, Norbert Galldiks, et al.
The Lancet. Oncology|August 29, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Nicholas Butowski, David D Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in GlioblastomaJian Wang, Tobias Weiss, Marian C Neidert, et al.
Swiss Medical Weekly|May 17, 2021
Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM)Silvia Hofer, Kristina Keller, Lukas Imbach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC TrialKaspar Draaisma, C Mircea S Tesileanu, Iris de Heer, et al.
Neuro-Oncology|June 28, 2022
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directionsAyal A Aizer, Nayan Lamba, Manmeet S Ahluwalia, et al.
Blood|September 26, 2018
Hyper-<i>N</i>-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphomaLorenz Thurner, Klaus-Dieter Preuss, Moritz Bewarder, et al.
Neuro-Oncology|July 18, 2020
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study designKurt A Jaeckle, Karla V Ballman, Martin van den Bent, et al.
The Lancet. Oncology|March 10, 2009
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialRoger Stupp, Monika E Hegi, Warren P Mason, et al.
Pageof 84

Showing results (711-720 of 831) with videos related to

Sort By:
Pageof 84
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2013
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapyMarkus Weiler, Jonas Blaes, Stefan Pusch, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 4, 2025
Availability and use of PET in patients with brain tumours - a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) surveyMaximilian J Mair, Philipp Lohmann, Norbert Galldiks, et al.
The Lancet. Oncology|August 29, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Nicholas Butowski, David D Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in GlioblastomaJian Wang, Tobias Weiss, Marian C Neidert, et al.
Swiss Medical Weekly|May 17, 2021
Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM)Silvia Hofer, Kristina Keller, Lukas Imbach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC TrialKaspar Draaisma, C Mircea S Tesileanu, Iris de Heer, et al.
Neuro-Oncology|June 28, 2022
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directionsAyal A Aizer, Nayan Lamba, Manmeet S Ahluwalia, et al.
Blood|September 26, 2018
Hyper-<i>N</i>-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphomaLorenz Thurner, Klaus-Dieter Preuss, Moritz Bewarder, et al.
Neuro-Oncology|July 18, 2020
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study designKurt A Jaeckle, Karla V Ballman, Martin van den Bent, et al.
The Lancet. Oncology|March 10, 2009
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialRoger Stupp, Monika E Hegi, Warren P Mason, et al.
Pageof 84